Perampanel in Brain Tumor-Related Epilepsy: A Systematic Review

Area of Science:

• Neuroscience
• Oncology
• Pharmacology

Background:

• Brain tumor-related epilepsy (BTRE) is a frequent comorbidity of brain neoplasms.
• Shared pathophysiological mechanisms, particularly glutamatergic pathways, link brain tumors and epileptogenesis.
• Glutamate AMPA receptor antagonism is a potential therapeutic target for both tumor growth and seizures.

Purpose of the Study:

• To systematically review preclinical and clinical evidence on perampanel (PER) in BTRE.
• To evaluate PER's antitumor properties, antiseizure effects, and tolerability.
• To identify gaps in current research regarding PER's role in BTRE.

Main Methods:

• Systematic review of preclinical (in vitro and in vivo) and clinical studies.
• Identification and synthesis of evidence on perampanel's efficacy and safety.
• Analysis of studies investigating PER's impact on tumor growth and epileptiform activity.

Main Results:

• PER demonstrates potential as an effective and well-tolerated antiseizure option for BTRE.
• In vitro studies suggest promising antitumor activity for PER.
• Preclinical models did not show PER slowing tumor progression; clinical data on antitumor effects are limited.

Conclusions:

• Perampanel (PER) is a potentially effective and generally well-tolerated treatment for brain tumor-related epilepsy (BTRE).
• While in vitro data suggest antitumor properties, its clinical efficacy in reducing tumor growth requires further investigation.
• Additional research is necessary to fully elucidate PER's role in managing brain tumors and associated epilepsy.